Clinical Trial Search

Primary: Tumor Marker CA125 — 189; 4 U/mL — p=<0.001

Primary: P16 Evaluation in Ovarian Germ Cell Tumors — 7; 4; 0; 6 units on a scale — p=0.001

Primary: Safety and Tolerability (Adverse Event Reported Per CTCAE v5) — 6; 0; 6; 6 Participants

Primary: Efficacy Patient Level — 26.9 percentage of participants

Primary: PFS — 29.8 Months

Primary: Tumor Response — 16.7 percentage of patients

Primary: Increase in SGK1 mRNA Expression Level — 1.5; 6.1 fold change

Primary: Number of Participants With Dose-Limiting Toxicity (DLT) — 0; 0; 0; 0 Participants

Primary: To Assess the Efficacy of TJ004309 Combined With Atezolizumab in a Cohort of Patients With Platinum-resistant IO Naive Ovarian Carcinoma and a Separate Biomarker…

Primary: Overall Response Rate (ORR) — 4 participants

Primary: Percentage of Patients That Achieve Maximal Surgical Debulking — 10 Participants

Primary: Number of Participants Assessed for Safety and Tolerability as Assessed by NCI CTCAE v3.0 — 3; 3; 4; 2 Participants

Primary: 6 Month Progression-free Survival (PFS) — 13 participants

Primary: Pathologic Complete Response Rates — 8 participants

Primary: Safety: Number of Participants With Freedom From Device and Procedure-related Major Adverse Events — 18 Participants — p=0.1309

Primary: Objective Tumor Response Rate (Complete and Partial Response) — 6.7 percentage of participants

Primary: Overall Survival — 32 months

Primary: Overall Survival — 2.14; 2.00 years

Primary: Number of Protocol Defined Adverse Events in Patients Receiving Neoadjuvant Carboplatin, Paclitaxel, and Bevacizumab — 7 protocol defined adverse events

Primary: Maximum-tolerated Dose of Pemetrexed With a Day 2 i.p. Cisplatin (75 mg/m2) and Day 8 i.p. Paclitaxel (60 mg/m2) — 500 mg/m2

Primary: Number of Participants With Reported Adverse Events by Type — 3; 3; 1; 1 Participants

Primary: Time to Progression (TTP)

Primary: Clinical Response Rate. — 0; 19; 21; 60 percentage of participants

Primary: Best Overall Tumor Response — 6; 25; 10; 5 participants

Primary: Objective Response (Complete Partial, Stable and Progression) — 1; 8; 10; 20 Participants

Primary: Number of Patients (%) in Which Sentinel Node(s) Are Detected After Injection of Blue Dye and Tracer in the Ovarian Ligaments. — 21 participants

Primary: Probability of Complete Clinical Response — 3.2 Percentage of Participants

Primary: Follicle Stimulating Hormone Stimulated Serum Inhibin B Levels. — 50.7; 48.8; 96.6; 47.7 participants

Primary: Progression-Free Survival (PFS) Assessed by Investigator as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) - Intent-to-Treat (ITT) Population…

Primary: Overall Response Rate — .083 proportion of participants